Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.51 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.47 |
| ▸ | SMO | Q99835 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29223830 | 0.83 | CYP17A1 (0.52) | MAP4K4CYP17A1EGFRSRCPSMB8 | |
| SCHEMBL15533892 | 0.82 | KDM4E (0.56) | SMO | |
| SCHEMBL4620977 | 0.82 | AAK1 (0.53) | MAP4K4CYP17A1AAK1EGFRSRC | |
| SCHEMBL4664375 | 0.82 | NPC1 (0.53) | MAP4K4CYP17A1EGFRSRCPSMB8 | |
| SCHEMBL5451118 | 0.81 | MAP2K7 (0.51) | MAP4K4CYP17A1MAPKAPK2CDK1 | |
| SCHEMBL12788367 | 0.80 | CYP17A1 (0.57) | MAP4K4CYP17A1AAK1EGFRSRC | |
| SCHEMBL4665750 | 0.80 | CYP1A2 (0.58) | MAP4K4EGFR | |
| SCHEMBL30252123 | 0.79 | CYP17A1 (0.46) | MAP4K4CYP17A1AAK1EGFRSRC | |
| SCHEMBL17457689 | 0.79 | CYP17A1 (0.46) | MAP4K4CYP17A1AAK1EGFRSRC | |
| SCHEMBL3183183 | 0.79 | CYP17A1 (0.56) | MAP4K4CYP17A1EGFRSRCSREBF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598202-B2 | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-03 | — | — | US | disclosed |
| EP-2254415-B1 | ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-23 | — | — | EP | disclosed |
| US-20090264429-A1 | Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264429-A1 | Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase | FAAH, FAAH2, HRH2 | MAP4K4 3664/4885CYP17A1 2394/4885AAK1 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.